Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06134492
Other study ID # ZKSJ0153
Secondary ID BMBF 01KG2301
Status Recruiting
Phase Phase 3
First received
Last updated
Start date February 20, 2024
Est. completion date December 2026

Study information

Verified date April 2024
Source Jena University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Almost 90 out of 100 people carry herpes simplex viruses (HSV). Once a person has been infected with the herpes viruses, he or she can't get rid of them for the rest of her/his life. For the most part, the viruses are in a dormant state. Only when the immune system is weakened, for example in the case of a serious illness or stress, are the viruses reactivated. They then mainly cause cold sores, which are harmless for healthy people and usually heal without therapy. However, especially in people with a weakened immune system, HSV can also cause serious infections, such as meningitis. In almost every second mechanically ventilated patient in intensive care who has pneumonia, HSV can be detected in the respiratory tract. This is caused by reactivation of the viruses as a result of the severe underlying disease and stress during intensive care therapy. Whether treatment of the herpes viruses (e.g. with acyclovir) is necessary in this situation and helps the patients to cure has not been clarified, especially as acyclovir can also cause side effects such as a deterioration in kidney function. Currently, the physicians decide to treat the herpes viruses in about half of the patients. Several studies have shown that patients for whom the physician decided to treat the viruses survived more often. However, all of these studies looked at the course of the disease only retrospectively and thus are subject to many biases (including physician selection of who receives treatment, missing data). A definitive conclusion as to whether herpesvirus therapy can be recommended cannot be drawn without doubt from these studies. Therefore, the investigators would like to investigate in a randomized controlled trial, i.e. patients are randomly assigned to the experimental (therapy of herpesviruses) or control group (no therapy of herpesviruses), the effect of therapy with acyclovir on survival in mechanically ventilated intensive care patients with lower respiratory tract infection (pneumonia) in whom a large amount of HSV was found in the respiratory tract. The goal of the study is to provide clarity on whether therapy will help patients recover.


Description:

Herpes-simplex virus (HSV) can be detected in the bronchoalveolar lavage (BAL) in up to 60% of mechanically ventilated (MV) ICU patients with a lower respiratory tract infection (LRTI), depending on the study population and the severity of disease. However, it remains unclear whether the detection represents a harmless viral shedding as a consequence of reactivation, reflecting the severity of the underlying disease and immunoparalysis, or a true clinical infection requiring antiviral therapy. To date, only retrospective studies have investigated the benefit of an antiviral therapy in HSV-positive ICU patients on mechanical ventilation (MV) with LRTI. In a retrospective study and additional meta-analysis on this topic a antiviral treatment was associated with an improved patient outcome, i.e.; lower all-cause hospital mortality (RR 0.74, 95% CI 0.64-0.85) and lower 30-day all-cause mortality (RR 0.75, 95% CI 0.59-0.94; 3 studies). Aim of this study is to determine prospectively in a multicenter, randomized controlled trial whether acyclovir therapy improves outcome in mechanically ventilated ICU patients with a LRTI and HSV detection in BAL. Overall, 710 ICU patients with MV and LRTI and HSV1-PCR-detection in BAL (>= 10E5 copies/ml) will be either randomized to receive acyclovir (10mg/kg body weight tid) for 10 days (or discharge from ICU if this is earlier) or no antiviral therapy (control group). Primary efficacy endpoint will be overall survival within 30 days comparing the acyclovir therapy and the control group. Secondary endpoints include ventilation-free days up to day 30, vasopressor-free days until day 30 and safety.


Recruitment information / eligibility

Status Recruiting
Enrollment 710
Est. completion date December 2026
Est. primary completion date July 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. = 18 years 2. Invasive ventilation expected for = 48 hours from time of randomization 3. PCR HSV-1 detection in BAL (>=10E5 copies/ml). 4. Pneumonia (community or healthcare acquired, incl. ventilator-associated pneumonia) 5. Written declaration of consent by the patient or legal representative Exclusion Criteria: 1. History of hypersensitivity to acyclovir or valacyclovir or other components of the investigational product. 2. Pregnancy/Lactation 3. Simultaneous participation in another interventional clinical trial 4. Decision to withhold life-sustaining therapies 5. Use of a virostatic agent (i.v. or p. os) with activity against herpes simplex (valacyclovir, famciclovir/penciclovir, brivudine, cidofovir, foscarnet) for therapeutic or prophylactic reasons at the time of randomization. 6. Solid organ transplantation, stem cell transplantation 7. Neutropenia (absolute neutrophil count <1500/µl (<1.5 × 109 /l) 8. Previous study participation in HerpMV

Study Design


Intervention

Drug:
Acyclovir
Dosage: 10mg/kg (current) body weight every 8 hours, dose adjustment to renal function according to technical information. Mode of administration: intravenous (i.v.)

Locations

Country Name City State
Germany Universitätsklinikum Augsburg Augsburg Bayern
Germany Evangelisches Klinikum Bethel Bielefeld Nordrhein-Westfalen
Germany Universitätsklinikum Bonn Bonn Nordrhein-Westfalen
Germany Universitätsklinikum Dresden Dresden Sachsen
Germany Universitätsklinikum Düsseldorf Düsseldorf Nordrhein-Westfalen
Germany Universitätsklinikum Essen Essen Nordrhein-Westfalen
Germany Universitätsklinikum Freiburg Freiburg Baden-Württemberg
Germany SRH Wald Klinikum Gera Gera Thüringen
Germany Universitätsklinikum Halle Halle Sachsen-Anhalt
Germany Universitätsklinikum Hamburg Eppendorf Hamburg
Germany Universitätsklinikum Heidelberg Heidelberg Baden-Württemberg
Germany Universitätsklinikum Heidelberg Heidelberg Baden-Württemberg
Germany Marien Hospital Herne, Universitätsklinikum der Ruhr-Universität Bochum Herne Nordreihn-Westfalen
Germany Universitätsklinikum Jena Jena Thüringen
Germany Universitätsklinikum Schleswig-Holstein Campus Kiel Kiel Schleswig-Holstein
Germany Universitätsklinikum Köln AöR Köln Nordrhein-Westfalen
Germany Universitätsklinikum Leipzig Leipzig Sachsen
Germany Universitätsklinikum Leipzig Leipzig Sachsen
Germany Universitätsklinikum Schleswig-Holstein Campus Lübeck Lübeck Schleswig-Holstein
Germany Klinikum der Ludwig-Maximilian-Universität München München Bayern
Germany Klinikum rechts der Isar München Bayern
Germany Klinikum rechts der Isar München Bayern
Germany Universitätsklinikum Münster Münster Nordrhein-Westfalen
Germany Universitätsklinikum Münster Münster Nordrhein-Westfalen
Germany Klinikum Nürnberg, Campus Nord Nürnberg Bayern
Germany Klinikum Nürnberg, Campus Süd Nürnberg Bayern
Germany Universitätsklinikum Regensburg Regensburg Bayern
Germany RoMed Klinikum Rosenheim Rosenheim Bayern
Germany Universitätsklinikum Tübingen Tübingen Baden-Württemberg

Sponsors (1)

Lead Sponsor Collaborator
Jena University Hospital

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary mortality (survival status) survival status day 30
Secondary Ventilation-free days days without mechanically ventilation via endotracheal tube, incl. tracheostoma day 30
Secondary Vasopressor-free days days without continuous vasopressor administration > 1h/day day 30
Secondary Delta SOFA score (Sepsis-related Organ Failure Assessment Score) Each of six organ systems receive a score ranging from 0 (normal) to 4 (most abnormal), with a minimum SOFA score of 0 and a maximum SOFA score of 24 Baseline - Day 10 or EOT if this event occurs earlier
Secondary Delta SOFA sub-score kidney (Sepsis-related Organ Failure Assessment Score) Sub-score for kidney function, the score ranges from 0 (normal) to 4 (most abnormal) Baseline - Day 10 or EOT if this event occurs earlier
Secondary Delta GFR value GFR value Baseline - Day 10 or EOT if this event occurs earlier
Secondary Length of stay in ICU days LOS in ICU day 30
Secondary Length of stay in Hospital days LOS in hospital day 30
Secondary Cost of intervention ICU and hospitalization days + acyclovir up to day 90
Secondary Days without delirium/coma based on CAM-ICU / RASS Until day 10 or until EOT if this event occurs earlier
Secondary Microbiological cure (EOT) Percent of participants with HSV eradication (PCR testing negative) in blood and respiratory tract At day 10 or day of EOT if this event occurs earlier
Secondary mortality (survival status) survival status 90 days
Secondary mortality (survival status) survival status 180 days
Secondary Quality of life (EQ-5D-5L) EuroQuality of Life Five Dimensions (EQ-5D-5L), the descriptive system comprises five dimensions (MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN / DISCOMFORT and ANXIETY / DEPRESSION), with five response levels: no problems, slight problems, moderate problems, severe problems, unable to/extreme problems. Measurement at day 10 or EOT if this event occurs earlier, day 30, day 90, and day 180
Secondary Incidence SAEs Incidence of serious adverse events From time of randomization until day 10 or EOT if this event occurs earlier
See also
  Status Clinical Trial Phase
Recruiting NCT03937947 - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Not yet recruiting NCT04057625 - Transthoracic Ultrasound in the Diagnosis and Follow-up of Ventilator Associated Pneumonia N/A
Not yet recruiting NCT03267693 - Gastrointestinal Complications in Association With Oropharyngeal and Respiratory Infections in Mechanical Ventilation N/A
Completed NCT00726167 - Serum Procalcitonin Study in the Management of Ventilated Patients N/A
Completed NCT02078999 - Biomarkers in Patients Undergoing Mechanical Ventilation N/A
Recruiting NCT05124977 - Antimicrobial Stewardship For Ventilator Associated Pneumonia in Intensive Care N/A
Recruiting NCT05331885 - A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2 Phase 3
Completed NCT05517759 - Application of VAP Bundle Among ICU Nurses
Active, not recruiting NCT04488510 - Pathogens Involved in Secondary Infections During Severe Forms of Covid-19 Pneumonia:
Completed NCT03917888 - Clinical Impact of Lung Ultrasound Monitoring for Diagnosis of VAP N/A
Not yet recruiting NCT06066489 - Effect of Educational Program About Preventive Care Bundle for Prevention of Ventilator Associated Pneumonia Among Newborns N/A
Completed NCT02096328 - Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia Phase 2
Terminated NCT00771719 - Open Label Pharmacokinetic in Adult Patients With Ventilator-Associated Pneumonia Phase 1
Recruiting NCT05696093 - Efficacy of Cotrimoxazole as a De-escalation Treatment of Ventilator-Associated Pneumonia in Intensive Care Unit Phase 3
Recruiting NCT05354778 - HYDROcortisone Versus Placebo for Severe HospItal-acquired Pneumonia in Intensive Care Patients: the HYDRO-SHIP Study N/A
Not yet recruiting NCT06059040 - Effect of Eliminating Gastric Residual Volume Monitoring on Ventilator Associated Events N/A
Completed NCT04563104 - Lung Ultrasound in Procalcitonin- Guided Antibiotic Discontinuation in Ventilator Associated Pneumonia
Terminated NCT01975350 - Efficacy Study of Colistimethate Sodium Inhalation in Patients With Ventilator-associated Pneumonia
Recruiting NCT06000761 - Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit N/A
Not yet recruiting NCT03294837 - Treatment of Ventilator Associated Pneumonia in Pediatric Intensive Care Unit N/A

External Links